Are Merck & Co., Inc. and Novartis AG (ADR) a Match Made in Health Care Heaven?

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Consolidation's been the name of the game around big pharma recently. Pfizer's (NYSE: PFE  ) made a name spinning off or selling its non-core businesses, selling its infant formula unit for nearly $12 billion back in 2012 and spinning off its animal health business into Zoetis (NYSE: ZTS  ) last year. It's been a strategy that has many investors thirsting for more from other top names around big pharma, and Novartis (NYSE: NVS  ) , one of the best in the business, is considering its own take on the divestment strategy.

Novartis is looking at potentially selling or otherwise dealing its animal health business to interested suitors. Merck's (NYSE: MRK  ) one such company that's sniffing around to add to its own formidable animal health group. While the two companies could hash out a sale, Novartis has been rumored to be exploring another possibility. According to a report from Bloomberg, Novartis is considering swapping its animal health business for Merck's over-the-counter unit, home to several top brands such as Coppertone and Claritin.

Is this rumored deal the best bet for Novartis and Merck investors? In the video below, Motley Fool contributor Dan Carroll talks about how this trade could be a great option for both companies -- and what investors should be on the lookout for from both Novartis and Merck going forward.

Is big pharma the biggest buy in dividend investing?
Big pharma stocks like Novartis and Merck have long been top dividend picks for long term investors. These stocks are great options: One of the dirty secrets that few finance professionals will openly admit is the fact that dividend stocks as a group handily outperform their non-dividend paying brethren. However, knowing this is only half the battle. The other half is identifying which dividend stocks in particular are the best. With this in mind, our top analysts put together a free list of nine high-yielding stocks that should be in every income investor's portfolio. To learn the identity of these stocks instantly and for free, all you have to do is click here now.

Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2791562, ~/Articles/ArticleHandler.aspx, 9/3/2015 2:49:53 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Dan Carroll

Dan began writing for the Motley Fool in 2012. He is a health care specialist who also follows the defense industry along with tracking the broader U.S. and international markets.

Today's Market

updated 5 hours ago Sponsored by:
DOW 16,351.38 293.03 1.82%
S&P 500 1,948.86 35.01 1.83%
NASD 4,749.98 113.87 2.46%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/2/2015 4:01 PM
MRK $52.98 Up +0.45 +0.86%
Merck & Co., Inc. CAPS Rating: ****
NVS $95.60 Up +0.92 +0.97%
Novartis CAPS Rating: ****
PFE $31.97 Up +0.61 +1.95%
Pfizer CAPS Rating: ****
ZTS $45.12 Up +1.14 +2.59%
Zoetis CAPS Rating: *****